Sepsis is a critical illness that begins with a simple infection and degenerates into a severe and dysregulated immune response that affects the whole body. This significant immune reaction typically causes widespread inflammation and can progress very rapidly. This can result in serious damage to tissues and organs, potentially leading to organ failure and death. Despite the severity of sepsis and its frequent poor prognosis, effective treatments are still elusive, and many sepsis patients remain at high risk of death and serious complications. Part of the issue is the complex cascade of cellular and biochemical events that underlie sepsis, which has made it difficult to obtain a comprehensive overview of the illness from which to design an effective treatment. Dr. Roberta Martinelli, Executive Director of Stromal Immunology and Early Discovery, Discovery Immunology, Merck, and colleagues, have published a study in the journal iScience which reveals new insights into the complex biological milieu underlying sepsis, and uncovers pathways and potential treatment targets that could change how we diagnose and treat this life-threatening illness.